top of page
(Teaser)-AI-in-Drug-Discovery-Focus-on-Oncology-Q3-2021 (1).png
One_Pager_Artificial_Intelligence_in_Drug_Discovery_Focus_on_Oncology (3).png

The main aim of this report is to profile an ecosystem of biotech companies and technology developers, applying advanced machine learning technologies to drug discovery in Oncology — one of the broadest therapeutic areas of pharmaceutical R&D and biotech investment.


According to World Health Organization (WHO), cancer is the leading cause of death globally, accounting for nearly 10 million deaths in 2020. It is the main reason why oncology has traditionally been the major focus of drug developers — oncology therapeutics being the largest category among all FDA-approved drugs last year (35%). It was found that oncology drug discovery has a 3.4% success rate on average however, it is expected that active implementation of AI in this area would increase this rate.


This overview highlights leading AI-driven companies, their investors, selected collaborations with pharma corporations, relative expertise of such companies, level of their funding, examples of deals and collaborations, as well as examples of AI applications. This is an overview analysis to help the reader understand what is happening in the industry currently and possibly give an idea of what is coming next.


The report is based on the online cloud-based analytics system (Dashboard), which incorporates the database of all entities featured in the report, and tens of thousands of data points about market trends, key developments, funding, deals, and more. While this report serves as an introduction to the area of AI-assisted oncology drug discovery, the underlying analytics system is updated on a daily basis and can be a powerful tool for monitoring the fast-paced industry.

bottom of page